ArticleLife (Basel, Switzerland)2026
Prevalence of Low Bone Density and Fracture Risk Assessed with the FRAX Tool in German Patients with Axial Spondyloarthritis: A Cross-Sectional Study.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Future Directions in Hypercalcemic and Normocalcemic Primary Hyperparathyroidism: FRAXplus for 10-Year Fracture Risk Assessment (A Retrospective Study).Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic inflammation in axial spondyloarthritis (axSpA) promotes osteoclast formation and bone resorption, leading to osteoporosis and an increased risk of fragility fractures. Osteoporotic fractures significantly impact the quality of life in patients with axSpA. While the Fracture Risk Assessment Tool (FRAX) is widely used to evaluate fracture risk, data on FRAX-based fracture risk assessment in axSpA, particularly in German patients, are limited.
objectiveThe primary objective of this study was to assess the prevalence of low bone mineral density (BMD) and fracture risk using FRAX for major osteoporotic fractures (MOF) and hip fractures (HF) in German patients with axSpA. Secondary objectives were to compare FRAX scores and BMD between genders and between patients with and without previous fractures, and to identify which FRAX parameters were most frequently abnormal. MATERIALS AND
methodsThis retrospective study analyzed demographic and clinical data, along with DXA-measured BMD, T-scores and Z-scores of the lumbar spine and femoral neck in 58 axSpA patients aged 43-81 years from routine clinical practice. Calculations for MOF and HF were performed using the FRAX model for Germany. Low BMD was defined as a T-score < -1 SD or a Z-score < -2 SD. Statistical analyses included independent
resultsThe mean age of patients was 65 years with a mean BMI of 29.5 kg/m
conclusionsThis study highlights the elevated fracture risk in axSpA patients assessed with FRAX. In this cohort, BMD alone was not associated with fracture history, suggesting that other factors-such as age, sex, glucocorticoid exposure, and prior fractures-may play a more prominent role. FRAX provides a valuable tool for evaluating fracture risk in axSpA, emphasizing the importance of a comprehensive assessment that incorporates both clinical risk factors and BMD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.